Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
04 2019
Historique:
received: 05 06 2018
revised: 13 11 2018
accepted: 18 11 2018
pubmed: 28 1 2019
medline: 18 4 2019
entrez: 28 1 2019
Statut: ppublish

Résumé

Evidence-based data describing patterns of recurrence and prognosis in women with FIGO stage IB2 to IIB locally advanced cervical cancer (LACC) are scarce. The purpose of this study was to analyse patterns of recurrence in LACC and their correlation with prognosis, depending on FIGO stage, lymph node (LN) status and treatment modalities. The endpoints of this study were the type of recurrence (locoregional or distant, and time to recurrence), the recurrence free survival, the overall survival and the cumulative incidence for both locoregional and distant recurrence. Data of women with FIGO stage IB2 to IIB CC treated between April 1996 and May 2016 were retrospectively abstracted from nine French institutions. The median follow-up for the 501 women included was 35.6 months. Recurrences were observed in 158 (31.5%), with a mean time to recurrence of 20.7 months. Women with IIB CC had poorer prognosis, lower 3-year RFS and higher 3-year cumulative incidence of both locoregional and distant recurrences. Women with positive or unknown LN status had poorer prognosis with higher 3-year cumulative incidence of distant recurrence. Women who underwent concomitant chemo-radiotherapy ± vaginal brachytherapy had poorer prognosis, with lower 3-year RFS and higher 3-year cumulative incidence of distant recurrence. Recurrence location and time to recurrence differ widely depending on the FIGO stage, LN status and treatment modalities, with potential impact on follow-up modalities and therapeutic approaches.

Identifiants

pubmed: 30685326
pii: S0748-7983(18)32012-2
doi: 10.1016/j.ejso.2018.11.014
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

659-665

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

Tiphaine de Foucher (T)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), 4 rue de la Chine, 75020, Paris, France.

Sofiane Bendifallah (S)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), 4 rue de la Chine, 75020, Paris, France; INSERM UMR_S_707, "Epidemiology, Information Systems, Modeling", University Pierre and Marie Curie, Paris 6, 27 rue de Chaligny, 75012, Paris, France. Electronic address: sofiane.bendifallah@aphp.fr.

Lobna Ouldamer (L)

Department of Obstetrics and Gynaecology, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2 bd Tonnellée, 37000, Tours, France.

Alexandre Bricou (A)

Department of Obstetrics, Gynecology and Reproductive Medicine, Hôpitaux Universitaires Paris Seine Saint-Denis, Assistance Publique-Hôpitaux de Paris, av du 14 juillet, 93140, Bondy, France.

Vincent Lavoue (V)

CRLCC Eugène-Marquis, service de gynécologie, CHU de Rennes, université de Rennes 1, av de la bataille Flandres-Dunkerque, 35000, Rennes, France.

Justine Varinot (J)

Department of Pathology, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, 4 rue de la Chine, 75020, Paris, France.

Geoffroy Canlorbe (G)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), 4 rue de la Chine, 75020, Paris, France.

Xavier Carcopino (X)

Department of Obstetrics and Gynaecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), CNRS, IRD, chemin des Bourrely, 13105, Marseille, France.

Emilie Raimond (E)

Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, 45 rue Cognacq Jay, 51100, Reims, France.

Laurie Monnier (L)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), 4 rue de la Chine, 75020, Paris, France.

Olivier Graesslin (O)

Department of Obstetrics and Gynaecology, Institute Alix de Champagne University Hospital, 45 rue Cognacq Jay, 51100, Reims, France.

Cyril Touboul (C)

Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal, Créteil, 40 av de Verdun, 94000, Créteil, France.

Pierre Collinet (P)

Department of Gynecologic Surgery, Jeanne de Flandre Hospital, CHU de Lille, av Eugène Avinée, 59000, Lille, France.

Marie-Emmanuelle Neveu (ME)

Department of Gynecology and Obstetrics, Kremlin-Bicêtre University Hospital, 78 rue du Général Leclerc, 94170, Le Kremlin-Bicêtre, France.

Cyrille Huchon (C)

Department of Obstetrics and Gynecology, Poissy-St Germain Hospital, 10 rue du champ Gaillard, 78000, Poissy, France.

Emile Daraï (E)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), 4 rue de la Chine, 75020, Paris, France; INSERM UMR_S_938, University Pierre et Marie Curie, Paris 6, 27 rue de Chaligny, 75012, Paris, France.

Marcos Ballester (M)

Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), University Pierre and Marie Curie, Paris 6, Institut Universitaire de Cancérologie (IUC), 4 rue de la Chine, 75020, Paris, France; INSERM UMR_S_938, University Pierre et Marie Curie, Paris 6, 27 rue de Chaligny, 75012, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH